Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
LY2584702 is an inhibitor of p70 ribosomal S6 kinase (p70S6K; IC50 = 0.004 µM).1 It is selective for p70S6K over a panel of 83 kinases. LY2584702 inhibits the phosphorylation of S6 in HCT116 colon cancer cells (IC50 = 0.1-0.24 µM) and decreases triglyceride levels and apolipoprotein B secretion in tuberous sclerosis complex 2 (TSC2) knockdown HepG2 cells.1,2 It suppresses self-renewal of primary mouse bone marrow stromal cells when used at a concentration of 2 µM.3 LY2584702 reduces tumor growth in an HCT116 colon cancer mouse xenograft model (ED50 = 2.3 mg/kg).1
WARNING This product is not for human or veterinary use.
1. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur. J. Cancer 50(5), 867-875 (2014).
2. Improvement of mTORC1-
3. Pharmacological inhibition of S6K1 impairs self-